4. What alternatives to acquisition could AB InBev have pursued? Speculate as to why a
takeover was the preferred option?
Answer: AB InBev could have pursued a “go it alone strategy” or a partnership as alternatives to a
merger. However, the former could have been viewed as too expensive and risky. Partnerships
required shared control and profit and often are hard to negotiate and fail as partner expectations
Ireland-Based Drug Maker Actavis Buys
U.S. Pharmaceuticals Firm Forest Labs
________________________________________________________________________
Case Study Objectives: To Illustrate
Alternative motives for cross-border acquisitions,
How taxes impact cross-border deals and capital flows, and
How activist investors can impact corporate decisions.
______________________________________________________________________________
Reflecting the escalating costs of developing blockbuster drugs (i.e., those with the potential to deliver
more than $1 billion in annual revenue) and the loss of patent protection on many substantial revenue
producing medications, the pharmaceutical industry has been undergoing a wave of consolidation for more
than a decade. The takeover strategy in many instances appeared to be largely formulaic: acquire rivals,
slash costs, and minimize taxes.
While Valeant Pharmaceuticals and Endo Health Solutions have employed this strategy effectively, drug
maker Actavis is the perhaps the most successful, tripling its market value during the last three years.
Actavis is a global, integrated specialty pharmaceutical company focused on developing, manufacturing,
and distributing generic and branded products in more than 60 countries. Structured as a holding company,
its global headquarters is located in Dublin, Ireland. The firm’s U.S. administrative headquarters is in
Parsippany, New Jersey. Actavis historically has focused on generic drugs, but in recent years it has
expanded through acquisition into branded drugs.
Actavis on February 18, 2014 announced that it had reached an agreement to buy Forest Laboratories
for $25 billion in cash and stock to create a pharmaceuticals firm with substantial exposure to branded and
generic drugs. Forest Labs is a fully integrated specialty pharmaceutical firm focused on the U.S. market,
with a portfolio of branded products. The combined revenues of the two specialty pharmaceutical
companies are expected to be more than $15 billion in 2015. The new company announced that it would be
increasing its annual budget for pharmaceutical research and development to more than $1 billion.
Strategically, Forest Labs represented an opportunity for Actavis to diversify into branded drugs and for
Forest Labs to penetrate foreign markets not currently survived. Forest Labs also has an impressive
number of drugs in the pipeline.